Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma

被引：1
|
作者：
Zhang, Yue [1 ]
Wu, Shenhong [1 ]
机构：
[1] Stony Brook Univ Hosp, Div Hematol & Oncol, Stony Brook, NY USA
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷
关键词：
OPEN-LABEL; MULTICENTER; NIVOLUMAB;
D O I：
10.21037/tcr.2019.06.39
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S585 / S588
页数：4
相关论文
共 50 条
  • [31] Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma REPLY
    Rini, Brian I.
    Powles, Thomas
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (26): : 2582 - 2582
  • [32] Sunitinib re-challenge in advanced renal-cell carcinoma
    Porta, C.
    Paglino, C.
    Gruenwald, V.
    BRITISH JOURNAL OF CANCER, 2014, 111 (06) : 1047 - 1053
  • [33] Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review
    Takahashi, Kenta
    Kato, Renpei
    Ikarashi, Daiki
    Matsuura, Tomohiko
    Maekawa, Shigekatsu
    Kanehira, Mitsugu
    Takata, Ryo
    Sugimura, Jun
    Abe, Takaya
    Obara, Wataru
    IJU CASE REPORTS, 2024, 7 (02) : 131 - 135
  • [34] Sunitinib re-challenge in advanced renal-cell carcinoma
    C Porta
    C Paglino
    V Grünwald
    British Journal of Cancer, 2014, 111 : 1047 - 1053
  • [35] Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma
    Spisarova, Martina
    Melichar, Bohuslav
    Vitaskova, Denisa
    Studentova, Hana
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (07) : 693 - 703
  • [36] Axitinib in advanced renal cell carcinoma: Outcomes following pazopanib or sunitinib.
    Laskey, Jennifer
    Venugopal, Balaji
    Thomson, Nicola
    O'Donoghue, Roisin
    Jones, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [37] Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK Perspective
    De Mello, Ramon Andrade
    Ayoub, Emili
    Castelo-Branco, Pedro
    De Almeida Zia, Victor Andre
    Savio, Andre
    Pozza, Daniel Humberto
    Tadokoro, Hakaru
    Teich, Nelson
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [38] Adjuvant Sunitinib in Renal-Cell Carcinoma
    Zhang, Sheng
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09): : 893 - 893
  • [39] Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
    Choueiri, T. K.
    Larkin, J.
    Pal, S.
    Motzer, R. J.
    Rini, B., I
    Venugopal, B.
    Alekseev, B.
    Miyake, H.
    Gravis, G.
    Bilen, M. A.
    Hariharan, S.
    Chudnovsky, A.
    Ching, K. A.
    Mu, X. J.
    Mariani, M.
    Robbins, P. B.
    Huang, B.
    di Pietro, A.
    Albiges, L.
    ESMO OPEN, 2021, 6 (03)
  • [40] MEDROXYPROGESTERONE PLUS TAMOXIFEN FOR ADVANCED RENAL-CELL CARCINOMA
    FUKS, JZ
    VANECHO, DA
    AISNER, J
    OSTROW, S
    WIERNIK, PH
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1982, 23 (MAR): : 154 - 154
12345